Market Trends of High Throughput Process Development Industry
This section covers the major market trends shaping the High Throughput Process Development Market according to our research experts:
Biopharmaceutical & Biotechnology Companies Segment Expected to Witness Significant Growth
The biopharmaceutical & biotechnology companies segment by the end-user is expected to witness significant growth over the analysis period. This is primarily attributed to the increase in R&D activities and spending by the companies and the emerging need to identify new drug targets for drug discovery.
Furthermore, significant factors augmenting the segment growth are a surge in the adoption of high throughput process development in these companies, the introduction of newer and advanced platforms, technological advancements in the fields of drug development, and growth in strategic developments by key players within the market. For instance, in November 2022, Mission Bio Inc., a pioneer in high-throughput single-cell DNA and multi-omics analysis, stated that AVROBIO's pipeline for lysosomal disorders deployed one single-cell transduction assay. Using Mission Bio's Tapestri Platform, the two firms worked together to create a precise, reproducible assay for measuring the proportion of transduced cells in samples made up of thousands of cells. At the 4th Annual Gene Therapy Analytical Development (GTAD) Summit, AVROBIO presented results on using this test to estimate the percentage transduction in autologous, lentiviral vector-mediated, genetically modified drug products.
Likewise, in June 2022, the United Kingdom's innovation agency, Innovate UK, gave a Smart grant to Orbit Discovery Ltd. This privately held biopharmaceutical firm specializes in identifying candidate peptide therapies using unique affinity and cell-based functional screening platforms. The funding, which has a total value of GBP 472,000 (~USD 579,474), will make it easier to use droplet-based microfluidics for cell-based functional screening and considerably increase the capacity and throughput of Orbit's peptide display platform. The high-throughput screening platform will target multi-membrane-spanning proteins such as G-protein-coupled receptors as difficult-to-access therapeutic targets in important biologically relevant areas.
In July 2022, Porvair Sciences, a manufacturer and developer of cutting-edge porous plastic materials and microplate technologies for the biotechnology and life science industries, introduced eGecko. This automated barcode application system offers the best high-throughput solution for accurately applying barcode labels onto racks of plates and petri dishes.
Such developments are contributing to the biopharmaceutical and biotechnology companies' growth over the forecast period.
North America Expected to Witness Significant Growth
North America is expected to dominate the market owing to various factors, such as the easy availability of technologically advanced products, the growth in the prevalence of chronic diseases, higher spending on research and development activities, the presence of prominent players in the region, and well-established healthcare infrastructure.
According to the article published by the Canadian Cancer Society in May 2022, an estimated 3,200 Canadians will be diagnosed with brain and spinal cord cancer by the end of 2022, including 1,850 men and 1,350 women. In addition, as per the source above, 27 Canadians are diagnosed with brain tumors every day. It is estimated that 55,000 Canadians are surviving with brain tumors. The high prevalence of brain tumors among the target population underlines the need for innovative therapies. This drives demand for new drug discovery and development, in turn boosting the adoption of high throughput process development among biopharmaceutical companies.
Furthermore, strategic initiatives by the regional companies augment the market's growth. For instance, in September 2022, Arsenal Biosciences, Inc. collaborated with Genentech. Genentech will deploy ArsenalBio's proprietary technology for high throughput process development and engineering of T-cells to identify critical success circuits in T-cell-based therapies. This discovery process employs the convergence of automation, large-scale genome engineering, and artificial intelligence algorithms to aid and advance the design, building, and testing of next-generation cell therapies for cancer.
In addition, Dynegene Technologies, with the first DNA high throughput synthesis expertise in China, was featured at the 2nd American Annual Conference of Human Genetics (ASHG). The company stated that the high throughput DNA synthesis technology of Dynegene Technologies would enter the United States market in the future to deliver overseas users high-quality, cost-effective products and services. It will provide robust support for synthetic biology, biomedical tools, molecular diagnostic materials, and other fields. Such developments are meant to speed up the use of high throughput process development across several end-users. Thus, owing to such developments, the North American region is expected to witness significant growth over the forecast period.
